Results 1 to 10 of about 6,800,049 (185)

Targeting farnesoid X receptor as aging intervention therapy [PDF]

Acta Pharmaceutica Sinica B
Environmental toxicants have been linked to aging and age-related diseases. The emerging evidence has shown that the enhancement of detoxification gene expression is a common transcriptome marker of long-lived mice, Drosophila melanogaster, and ...
Lijun Zhang, Jing Yu, Xiaoyan Gao, Yingxuan Yan, Xinyi Wang, Hang Shi, Minglv Fang, Ying Liu, Young-Bum Kim, Huanhu Zhu, Xiaojun Wu, Cheng Huang, Shengjie Fan   +12 more
doaj   +3 more sources

Farnesoid X receptor (FXR): Structures and ligands

Computational and Structural Biotechnology Journal, 2021
Farnesoid X receptor (FXR) is a bile acid activated nuclear receptor (BAR) and is mainly expressed in the liver and intestine. Upon ligand binding, FXR regulates key genes involved in the metabolic process of bile acid synthesis, transport and ...
Longying Jiang, Huajun Zhang, Desheng Xiao, Hudie Wei, Yongheng Chen   +4 more
doaj   +3 more sources

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota

Metabolites, 2022
Obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) are characterized by the concepts of lipo- and glucotoxicity. NAFLD is characterized by the accumulation of different lipidic species within the hepatocytes. Bile acids (BA), derived
Hideki Mori, Gianluca Svegliati Baroni, Marco Marzioni, Francesca Di Nicola, Pierangelo Santori, Luca Maroni, Ludovico Abenavoli, Emidio Scarpellini   +7 more
doaj   +2 more sources

Hyodeoxycholic acid relieves neuropathic pain by activating farnesoid X receptor signaling [PDF]

Journal of Advanced Research
Background: Neuropathic pain, is a chronic condition stemming from nervous system injuries. The farnesoid X receptor (FXR), primarily expressed in the liver and intestines, plays a crucial role in regulating bile acids and lipids metabolism.
Jiaqi Lin, Xuejiao Zeng, Zehua Su, Xin Li, Yongze Yu, Shuwen Qian, Qianhao Hou, Wenying Duan, Zetian Wang, Chunzheng Liu, Jinyuan Zhang, Changshun Huang, Lijun Liao   +12 more
doaj   +2 more sources

Computational study of novel natural agonists targeting farnesoid X receptor [PDF]

Scientific Reports
The farnesoid X receptor (FXR) is a crucial therapeutic target for treating non-alcoholic steatohepatitis (NASH). Although obeticholic acid (OCA) as a FXR agonist presents good efficacy, the safety data such as severe pruritus should be carefully ...
Xindan Hu, Junliang Ge, Ying Wen
doaj   +2 more sources

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor

Frontiers in Pharmacology, 2022
Nuclear receptors (NRs) are a superfamily of transcription factors induced by ligands and also function as integrators of hormonal and nutritional signals.
Jianglian She, Jianglian She, Tanwei Gu, Xiaoyan Pang, Yonghong Liu, Yonghong Liu, Yonghong Liu, Lan Tang, Xuefeng Zhou, Xuefeng Zhou   +9 more
doaj   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression

Hepatology, EarlyView., 2022
Improved mitochondrial activity, due to the lack of methylation‐controlled J protein (MCJ), creates a specific microbiota signature that when transferred through cecal microbiota transplantation delays NASH progression by restoring the gut‐liver axis and enhancing hepatic fatty acid oxidation.
María Juárez‐Fernández, Naroa Goikoetxea‐Usandizaga, David Porras, María Victoria García‐Mediavilla, Miren Bravo, Marina Serrano‐Maciá, Jorge Simón, Teresa C. Delgado, Sofía Lachiondo‐Ortega, Susana Martínez‐Flórez, Óscar Lorenzo, Mercedes Rincón, Marta Varela‐Rey, Leticia Abecia, Héctor Rodríguez, Juan Anguita, Esther Nistal, María Luz Martínez‐Chantar, Sonia Sánchez‐Campos   +18 more
wiley   +1 more source

Genetic predisposition to porto‐sinusoidal vascular disorder: A functional genomic‐based, multigenerational family study

Hepatology, EarlyView., 2022
A deleterious variant of FCHSD1 results in mTOR pathway overactivation and may cause porto‐sinusoidal vascular disorder (PSVD). The pedigree of the family demonstrated an autosomal dominant disease with variable expressivity. Whole‐genome sequencing and Sanger sequencing both validated the existence of the FCHSD1 variant and the heterozygosity of c ...
Jingxuan Shan, André Megarbane, Aziz Chouchane, Deepak Karthik, Ramzi Temanni, Atilio Reyes Romero, Huiying Hua, Chun Pan, Xixi Chen, Murugan Subramanian, Chadi Saad, Hamdi Mbarek, Cybel Mehawej, Eliane Chouery, Sirin W. Abuaqel, Alexander Dömling, Sami Remadi, Cesar Yaghi, Pu Li, Lotfi Chouchane   +19 more
wiley   +1 more source